KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Revenue: 2019-2025

Historic Revenue for Royalty Pharma (RPRX) over the last 7 years, with Sep 2025 value amounting to $609.3 million.

  • Royalty Pharma's Revenue rose 7.90% to $609.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 billion, marking a year-over-year increase of 3.70%. This contributed to the annual value of $2.3 billion for FY2024, which is 3.86% down from last year.
  • Per Royalty Pharma's latest filing, its Revenue stood at $609.3 million for Q3 2025, which was up 5.29% from $578.7 million recorded in Q2 2025.
  • Royalty Pharma's Revenue's 5-year high stood at $684.0 million during Q1 2023, with a 5-year trough of $536.0 million in Q2 2022.
  • Over the past 3 years, Royalty Pharma's median Revenue value was $568.2 million (recorded in 2025), while the average stood at $579.5 million.
  • Its Revenue has fluctuated over the past 5 years, first climbed by 21.69% in 2023, then fell by 16.96% in 2024.
  • Royalty Pharma's Revenue (Quarterly) stood at $575.7 million in 2021, then dropped by 1.73% to $565.7 million in 2022, then climbed by 5.36% to $596.1 million in 2023, then declined by 0.41% to $593.6 million in 2024, then grew by 7.90% to $609.3 million in 2025.
  • Its Revenue stands at $609.3 million for Q3 2025, versus $578.7 million for Q2 2025 and $568.2 million for Q1 2025.